Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q2 2021 · 10-Q
Revenue$8.76M$8.76Mno prior Q2 2020 on file Net Income-$10.95M-$10.95MN/M vs Q2 2020 EPS Diluted-$0.33-$0.33N/M vs Q2 2020 Operating Income-$11,051,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,508,000— Margins · derivedOperating margin-126.2%
Net margin-125.0%
ended Jun 30, 2021 · filed Aug 10, 2021 · 41 d after period end